Education
About Us
Working with TipRanks
Follow Us
Urogen Pharma (URGN)
NASDAQ:URGN
Earnings Data
Report Date
Nov 17, 2025Before Open (Confirmed)
Period Ending
2025 (Q3)Consensus EPS Forecast
-0.64Last Year’s EPS
-0.55Same Quarter Last Year
Strong Buy
Based on 6 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
The earnings call highlighted significant achievements, including FDA approval of ZUSDURI and strong revenue growth for JELMYTO. However, these were balanced by challenges such as reimbursement issues for ZUSDURI and increased operating expenses, resulting in a larger net loss.Company Guidance
FDA Approval of ZUSDURI
ZUSDURI was approved for adults with recurrent low-grade intermediate risk non-muscle invasive bladder cancer, marking a significant milestone for UroGen and offering a new treatment paradigm.
Strong JELMYTO Revenue Growth
JELMYTO achieved net product revenues of $24.2 million in Q2 2025, representing an 11% increase over the same period in 2024.
Expansion of Sales Force
The sales team expanded from 50 to 82 territories to support the launch of ZUSDURI, positioning the company to reach a broader market.
Positive Clinical Data for ZUSDURI
In the pivotal Phase III ENVISION trial, 79% of patients achieved a complete response at 3 months, with a 24-month duration of response of 72.2%.
Robust Cash Position
UroGen maintains a strong balance sheet with $161.6 million in cash, cash equivalents, and marketable securities as of June 30, 2025.
URGN Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
URGN Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Aug 07, 2025 | $20.01 | $18.59 | -7.10% |
May 12, 2025 | $10.38 | $11.14 | +7.32% |
Mar 10, 2025 | $9.82 | $9.92 | +1.02% |
Nov 06, 2024 | $12.21 | $12.24 | +0.25% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Urogen Pharma (URGN) report earnings?
Urogen Pharma (URGN) is schdueled to report earning on Nov 17, 2025, Before Open (Confirmed).
What is Urogen Pharma (URGN) earnings time?
Urogen Pharma (URGN) earnings time is at Nov 17, 2025, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is URGN EPS forecast?
URGN EPS forecast for the fiscal quarter 2025 (Q3) is -0.64.